Search Results - "Sridhar, Shaarwari"
-
1
A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
Published in Frontiers in immunology (12-12-2023)“…Immune checkpoint therapies have led to significant breakthroughs in cancer patient treatment in recent years. However, their efficiency is variable, and…”
Get full text
Journal Article -
2
Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors
Published in Frontiers in immunology (2024)“…[This corrects the article DOI: 10.3389/fimmu.2023.1311658.]…”
Get full text
Journal Article -
3
879 A promising cancer immunotherapy target: novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27
Published in Journal for immunotherapy of cancer (01-11-2021)“…BackgroundCD27 is a member of the TNF receptor superfamily and plays a critical role in T-cell activation by providing a costimulatory signal. CD27 signaling…”
Get full text
Journal Article -
4
VISTA a Potential New Immuno-Oncology Target in Acute Myeloid Leukemia
Published in Blood (02-11-2023)“…V-domain Immunoglobulin Suppressor of T cell Activation (VISTA/PD-1H) is a B7 family member highly expressed on circulating and intra-tumoral myeloid cells…”
Get full text
Journal Article -
5
Abstract P21: VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid Leukemia
Published in Blood cancer discovery (04-03-2024)“…Abstract V-domain Immunoglobulin Suppressor of T cell Activation (VISTA/PD-1H) is a co-inhibitor molecule of the B7 family member highly expressed on…”
Get full text
Journal Article -
6
Abstract 1637: A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors
Published in Cancer research (Chicago, Ill.) (01-07-2021)“…Abstract V-domain Immunoglobulin Suppressor of T cell Activation (VISTA/PD-1H) is an immune checkpoint regulator of the B7 family. VISTA can be found on the…”
Get full text
Journal Article -
7
Abstract 4261: CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Published in Cancer research (Chicago, Ill.) (15-06-2022)“…Abstract CD27 is a member of the TNF-receptor superfamily, highly expressed on CD4+ and CD8+ T cells as well as on NK and NKT cells. It plays a key role on T…”
Get full text
Journal Article -
8
Abstract 972: VISTA expression in patients with advanced solid tumors: A potential biomarker in VISTA-101 clinical trial
Published in Cancer research (Chicago, Ill.) (04-04-2023)“…Abstract V-domain Immunoglobulin Suppressor of T cell Activation (VISTA/PD-1H) is a B7 family member highly expressed on circulating and intra-tumoral myeloid…”
Get full text
Journal Article -
9
182 Highly potent fully human anti-VISTA antibodies – a new target checkpoint inhibitor against immunosuppressive myeloid cells
Published in Journal for immunotherapy of cancer (01-11-2020)“…BackgroundV-domain Immunoglobulin Suppressor of T cell Activation (VISTA/PD-1H) is a B7 family ligand expressed on circulating and intratumoural myeloid cells…”
Get full text
Journal Article -
10
Abstract B18: Combining selective toll-like receptor 9 (TLR9) agonists and GM-CSF activity for potentiating cellular activation in active cell immunotherapy (ACI)
Published in Cancer research (Chicago, Ill.) (01-01-2013)“…Abstract Sipuleucel-T (Provenge®), indicated for the treatment of asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer, is the…”
Get full text
Journal Article